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ABSTRACT 
The effects of three commonly used corticosteroid preparations on the pituitary- adrenal 
" axis and the skin were studied following graded intradermal injections. Betamethasone 
acetate-phosphate suspension was more suppressive to the pituitary-adrenal axis than 
equivalent doses of either triamcinolone acetonide or triamcinolone diacetate. However, the 
long-term local effects of intradermal corticosteroids (hypopigmentation, atrophy. telangiec-
tasia) were more marked following the use of the triamcinolone formulations. 
The intralesional injection of corticosteroid 
:.J preparations was found to be therapeutically use-
ful in a number of dermatologic diseases over 15 
years ago [1 ]. Since that time this has become 
standard treatment for many cutaneous lesions. 
"' The side effects of orally administe red corticoste-
. roids are well known [2], and the effects of topical 
corticosteroids applied under polyethylene occlu-
~ sion are also well documented [3-6]. However. 
desptte the common use of intralesional steroids, 
there is lillie in the literature to document the 
degree and duration of pituitary-adrenal axis sup-
~ pression resulting from their use, and only scat-
tered reports of the residual changes induced at the 
site of injection [7, 8 ]. In this study we investigated 
-. the response of the pituitary-adrenal axis and the 
residual clinical effects on the skin following intra-
dermal injections of small, graded amounts of 
three commonly employed cortocosleroid prepara-
tions: triamcinolone acetonidet. triamcinolone 
diacetatet, and betamethasone acetate- phosphate 
~ suspension§. 
MATERIALS 1\NO METIIODS 
Eight normal male volunteers between the ages 25 and 
35 years. none of whom had previously received cortico-
steroid preparations, were selected for study. Three 
preparations were investigated: triamcinolone acetonide 
.. 40 mg/ml (TCAl. triamcinolone diacetate 40 mg/ml 
(TCDA). and betamethasone acetate-phosphate !.USpen-
sion 6 mg/ml (BAP). 
Serum cortisol levels were determined at 24-hr inter-
- vals for four days following a single 8:00a.m. intradermal 
injection of 0.1 cc, 0.2 cc. or 0.5 cc of the corticosteroid 
preparation under study. Intradermal mjection sites were 
on the ventral forearm or the lateral buttock. To assure 
, return of pituitary-adrenal axis function to normal. a 
2-week interval free of steroid administration was inter-
posed between the period of study for each preparation. 
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Serum cortisol was measured by a competitive protein -
binding radioassay method that shows no cross-reaction 
with the synthetic steroids used in this study [9]. 
The injection sites were observed over a period of 24 
months and clinical changes were recorded. 
RESULTS 
Clinical 
Hypopigmentation and atrophy became appar-
ent in the sites of injection of all three preparations 
within 14-21 days (Fig. 1). Telangiectasia ap-
peared after 1 month. In the triamcinolone-
injected sites, atrophy and telangiectasia became 
progressively more severe over 6 months. The 
changes stabilized and remained unchanged with 
little evidence of resolution after 1 vear. Yellow-
white, chalky deposits became evident in the 
atrophic injection sites and in some instances 
resolved after 2 years. The BAP areas slowly 
become less apparent and after 1 year the only 
residual change was faint hypopigmentation in 2 of 
the 8 subjects. 
Pituitary-Adrenal Function 
Neither triamcinolone acetonide (40 mg/ml) nor 
triamcinolone diacetate (40 mg/ml) injected intra-
dermally at 8:00a.m. into normal skin at doses of 
4.0 mg {0.1 ml) to 20.0 mg (0.5 ml) produced 
significant deviation of serum cortisol values from 
the range of normal (8-20 11g'lt) when measured at 
24-hr intervals for -1 days following injection (Fig. 
2). 
The intradermal injection ofbetamethasone ace-
tate-phosphate suspension (6 mg/ml) at a dose of 
0.6 mg (0.1 ml) produced no change in serum 
cortisol values. Twenty-four hours after the injec-
tion of 1.2 mg (0.2 ml), 8: 00 a.m. serum cortisol 
values ranged between 1.5 and 6.5 micrograms 
% in all 8 subjects studied. At 48 hr, all values had 
returned Lo normal. Twenty-four hr after the injec-
tion of 3.0 mg (0.5 ml) betamethasone acetate-
phosphate suspensiop, cortisol values ranged be-
tween 0.5 and 2.0 micrograms % in aU 7 subjects 
studied. At 48 hr, 4 values were still below the lower 
range of normal, and at 72 hr, 2 values were below 
normal. By 96 hr the cortisol values had returned 
to normal (Fig. 3). 
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FIG. 1: Three sites of hypopigmentation and atrophy 
one month after injection of betamethasone acetate-
phosphate suspension. Necrosis of epidermis (lower 
single lesion) one week after injection of 20 mg (0.5 ml) 
triamcinolone acetonide. 
DJSCllSSION 
Clinical 
Hypopigmentation, atrophy. and telangiectasia 
in the skin following intradermal injections of 
triamcinolone have been reported previously [8]. 
In this studv with triamcinolone acetonide. triam-
cinolone di~cetate, and betamethasone acetate-
phosphate suspension the same local changes were 
noted. However, they were much more marked at 
the sites of triamcinolone injection than in the 
areas injected with betamethasone. After I year of 
observation, virtually all hypopigmented and 
atrophic changes in the betamethasone-injected 
sites had resoh·ed. while after 2 years most sites of 
triamcinolone injection still manifested atrophy 
and telangiectasia. At times following the higher 
doses of the triamcinolone compounds, hypopig-
mentation and atrophy in an arborized and linear 
array developed proximally along veins and lym-
phatics. 
Guin. Knox, Chernosky, and Shapiro [10) re-
ported residual, chalky-white deposits in the skin 
following intradermal injection with prednisolone 
acetate. In the present study similar central. 
chalky deposits were seen in the sites of triamcino-
lone injection. hut not in the sites of betametha-
:>one injectiun. Larger deposits left after TCA ur 
TCDA injections occasionally ruptured through 
the overlying atrophic epidermis and drained. 
After 2 yean; smaller deJ>OSits left from lower dose 
injections were often still present. 
The glucocorticoid moiety in TCA and TCDA is 
physiologically inactive until deacetonization or 
deacetylation. respectively. has taken place. 
Hence, the active triamcinolone salt is released 
slowly in the injection site from its inert conjugated 
slate by a process of enzymatic degradation. The 
same applies to the acetylated betamethasone 
moiety in BAP. However. one-half of the dose of 
BAP is betamethasone phosphate, a readily ab-
sorbed. physiologically active compound. Thus 50 
percent of the injected dose of BAP is rapidly 
absorbed w1d removed from the local area. In this 
study the triamcinolone preparations induced 
much more severe local changes than did the BAP. 
presumably because the entire amount of triam 
cinolone is released slowly in the local area, 
whereas one-half the administered dose of BAP is 
rapidly absorbed and removed from the skin. 
All volunteers spontaneously noted a burning 
discomfort associated with the intradermal injec-
tion of betamethasone salts; injection oftriamcino-
lone compounds was relatively painless. 
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The Pituilaf)-.-tdrrnal Ari,· 
• The mtradermal injection of 20 mg or Je,.,. of 
~TCA or TCDA result in no suppn·3ion ol pitui-
tary- adrenal function 8!1 indicated by subsequent 
daily assays of serum cortisol (Fi~ . 21 . However. 
similar injection nf physiologicnll} ~maller 
"'amnunl!l uf BAP rl•sults in mnrkecl plluitnr~ adre-
nal liUppreP.sion, till' durnlion of which IS dose 
• related (Fig. 3) • 
._ Intradermal in)l'Ction ul' 1.2 m~t Ho\P iequivalent 
to 8.0 mg triamrinulom·) Ill I re!'ults in UJipression 
~ of ~<erum cortisol values at 24 hr with return to 
normal value;. at ·18 hr. lnjl·rtinn nl :1.0 mg BAP 
-(equivalem to 20.0 mg triamcinulonel suppresses 
corti ol \'Blue:: lor UJI to i2 hr. 
At tlw clinicnllv relc~\·nnt, lo\\ intradermal do,;es 
• utilized in thi.~ · tudy, BAP had n more potent 
-;;uppressi\'e effect on pit uitarv- adrcnal lunct ion 
~than the triamcinolum· rm.•parat ions. At much 
higher do~e,., Zaynoun and Salt i 11 ~I oh,-crved I he 
...... arne phenomenon. The mure potent uppressive 
effect of BAP is pre,.,umBbly due to the rapidly 
~ absorhNl betttml'l hasonl' l>h•bphate salt which is 
deli' ered tn the pituitary gland when· it induces 
ktt'edhack "llppret\~ion nt adrenal ~euet ion . 
Despite uur dul o ohtuined folluwm~: lu\\ dol>e 
• intradcrmal triomicinolone injections, pitui-
~ tary- adrenal suppression after injection of higher 
amounts of such compounds does ot•cur Mt'Gugan. 
.. Shu. ter, nnd Bot toms 11:J) reportt·d suppre!'sion 
"Aith TCA at dt*cS nf 50 mg and nho\'l' with no 
~ t.uppres,ion from 2.') mg TCDA. c:m and Baxter 
11·11 outed persisting suppression of crum cortisol 
levels at 9() hr aft t•r the injection of ·15 mg TCA. 
The recuverv time Willi no1 determined. Potter [15] 
reported do;e- rcspunse cur"~ with TCA injections 
inw ncne cy,.,t. . 15 mg produced no suppression 
while 50 mg :-uppr ·d cortL-.QI le\'el for 6 day!'. 
Mikhail et al [16) proposed that intramuscular 
injcl·tiun with TCA rt.-sulted in more prolonged 
supprcs!'illn than \\lth TCDA, becnu~e the proces:; 
ol deacctonization is sluw!'r than that of dencetyla-
tion. 
In 19115 ~ichol-. ~ugcnt. and Tyler Ill I reported 
d iurnal variation in the degree of adrenal suppre;-
sion induced bv the administration ol steroids. A 
dn:-E.> delivered ~t 8 :00 n.m. suppre,.~e~ le~ than an 
equ1vnlcnt dosu given in the afternoon The data 
rl:'portecl in this ~t udy Wl:'rc obtained following 8:00 
a.m. injections. Huwever. 2 volunteers were in-
jertl:'d with 1.2 mg (0.2l·rl ofBAP at \ ;00 p .m . and 
no dilfl•rence in the degree or durat ion of adrenal 
suppres,:ion wa,. ohl'-1'1'\'00. 
Tlw £•fiicacy of im·oq)()rat ion of a rapidly ab-
sorbed, physiolol(it.-ally active glucocorticoid moiety 
in a :.teroid preparution for intralcsionnl injection 
j,., que,.tinnable. :\lo l h .. ions for which intrale-
"ional ,teroid injection are employed are chronic 
and indolent. Thcrcfnre, n conjugated compound 
wnirh i slowly degraded in the local area seem5 
prl.'ferahle. Furthl•rmon•, 11 ... teroid administered in 
a lm\ do,.,c which doCh not suppre:ss endogenous 
adn•nncmtkal . t'crction nets adnitiwly with the 
nurmnllv cirrulating lcveb of l·ortb~me (18 J. Be· 
t1!methn,.one acetate- phosphate suspension rap-
idly inhibits adrenocorticnl secrrtion and. conse-
quently, lower: endngl'l\flll" steroid levels. lntra-
dermnl injection of BAJ> c-auses a st iOJ:IOR pain. but 
the long-lerm loC'ul rm1r.equencell of hypopigmen· 
tntinn, atrophy, nnd lclnngiet·tasin are notably less 
with thL'l mixtun· than with tnamicinolone salts. 
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